Transplant Genomics Inc. has appointed well-known transplant physician Roy First, MD, as its Chief Medical Officer as the company moves toward the launch of its first product, the TruGraf Blood Test. Most recently, First was the Vice President and Therapeutic Area Leader of Transplantation at Astellas Pharma Global Development, Inc. He is a past president of the American Society of Transplantation and recipient of the AST Lifetime Achievement Award.
“I am very excited to be joining this innovative company on the cutting edge of applying genomic biomarkers to post-transplant management,” said First. “The ultimate goal is to be able to detect and respond to early signs of graft injury so as to improve management of the patient as well as graft outcomes. I am convinced that TruGraf has such capabilities and has the potential to extend graft and patient lives, and reduce health care costs.”
TruGraf is a blood test for kidney transplant recipients and uses gene expression profiling to provide decision support for physicians in their efforts to personalize immunosuppressive therapy.